Lijoy Varghese

404 total citations
19 papers, 297 citations indexed

About

Lijoy Varghese is a scholar working on Epidemiology, Dermatology and Infectious Diseases. According to data from OpenAlex, Lijoy Varghese has authored 19 papers receiving a total of 297 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Epidemiology, 6 papers in Dermatology and 5 papers in Infectious Diseases. Recurrent topics in Lijoy Varghese's work include Herpesvirus Infections and Treatments (10 papers), Acne and Rosacea Treatments and Effects (6 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Lijoy Varghese is often cited by papers focused on Herpesvirus Infections and Treatments (10 papers), Acne and Rosacea Treatments and Effects (6 papers) and SARS-CoV-2 and COVID-19 Research (3 papers). Lijoy Varghese collaborates with scholars based in Belgium, Germany and Singapore. Lijoy Varghese's co-authors include Desmond Curran, Desirée Van Oorschot, Baudouin Standaert, Alfred von Krempelhuber, Justin Carrico, Barbara P. Yawn, Brandon J. Patterson, Philip O. Buck, Katherine A. Hicks and Rómulo E. Colindres and has published in prestigious journals such as SHILAP Revista de lepidopterología, Vaccine and International Journal of Infectious Diseases.

In The Last Decade

Lijoy Varghese

19 papers receiving 294 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lijoy Varghese Belgium 9 234 103 69 46 38 19 297
Justin Carrico United States 10 191 0.8× 42 0.4× 34 0.5× 10 0.2× 98 2.6× 32 292
Ashleigh McGirr Canada 8 224 1.0× 29 0.3× 30 0.4× 13 0.3× 32 0.8× 14 283
M. Uhart France 12 326 1.4× 39 0.4× 28 0.4× 8 0.2× 85 2.2× 29 404
Stephen Kegg United Kingdom 4 173 0.7× 34 0.3× 28 0.4× 51 1.1× 15 0.4× 11 236
Ryan Thompson United States 8 127 0.5× 20 0.2× 49 0.7× 12 0.3× 3 0.1× 13 208
Doreen Fernsler United States 5 118 0.5× 20 0.2× 10 0.1× 12 0.3× 4 0.1× 10 138
Fernanda Hammes Varela Brazil 5 216 0.9× 24 0.2× 6 0.1× 19 0.4× 10 0.3× 8 238
L Izaley Democratic Republic of the Congo 7 214 0.9× 42 0.4× 59 0.9× 99 2.2× 1 0.0× 9 358
Wirach Maek-a-nantawat Thailand 11 150 0.6× 6 0.1× 21 0.3× 95 2.1× 10 0.3× 28 395
Steven J. Sperber United States 9 118 0.5× 22 0.2× 3 0.0× 22 0.5× 6 0.2× 16 266

Countries citing papers authored by Lijoy Varghese

Since Specialization
Citations

This map shows the geographic impact of Lijoy Varghese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lijoy Varghese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lijoy Varghese more than expected).

Fields of papers citing papers by Lijoy Varghese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lijoy Varghese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lijoy Varghese. The network helps show where Lijoy Varghese may publish in the future.

Co-authorship network of co-authors of Lijoy Varghese

This figure shows the co-authorship network connecting the top 25 collaborators of Lijoy Varghese. A scholar is included among the top collaborators of Lijoy Varghese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lijoy Varghese. Lijoy Varghese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
2.
Varghese, Lijoy, et al.. (2023). Cost-Effectiveness of Empagliflozin on Top of Standard of Care for Heart Failure With Reduced Ejection Fraction in Singapore. Value in Health Regional Issues. 34. 108–117. 1 indexed citations
3.
Standaert, Baudouin, Christophe Sauboin, Rodrigo DeAntonio, et al.. (2020). How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future. SHILAP Revista de lepidopterología. 8(1). 1719588–1719588. 18 indexed citations
4.
Varghese, Lijoy, et al.. (2020). Applying a Constrained Optimization Portfolio Model to Aid Prioritization of Public Health Interventions in Malaysia. Value in Health Regional Issues. 21. 172–180. 6 indexed citations
5.
Quiambao, Beatriz P., et al.. (2020). Health economic assessment of a rabies pre-exposure prophylaxis program compared with post-exposure prophylaxis alone in high-risk age groups in the Philippines. International Journal of Infectious Diseases. 97. 38–46. 7 indexed citations
6.
McGirr, Ashleigh, Desirée Van Oorschot, M. Stokes, et al.. (2019). Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults. Applied Health Economics and Health Policy. 17(5). 723–732. 28 indexed citations
7.
Kim, Yun Kyung, et al.. (2018). Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics. 36(12). 1475–1490. 14 indexed citations
8.
9.
Oorschot, Desirée Van, et al.. (2018). PIN53 - IS THE RECOMBINANT ZOSTER VACCINE ALSO COST-EFFECTIVE FOR THE GERMAN POPULATION ≥50 YEARS OF AGE?. Value in Health. 21. S230–S230. 1 indexed citations
10.
Watanabe, Daisuke, Akiko Mizukami, Katsiaryna Holl, et al.. (2018). The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis. Dermatology and Therapy. 8(2). 269–284. 15 indexed citations
11.
Curran, Desmond, Brandon J. Patterson, Lijoy Varghese, et al.. (2018). Cost-effectiveness of an Adjuvanted Recombinant Zoster Vaccine in older adults in the United States. Vaccine. 36(33). 5037–5045. 53 indexed citations
12.
Oorschot, Desirée Van, et al.. (2018). Cost-effectiveness of the recombinant zoster vaccine in the German population aged ≥60 years old. Human Vaccines & Immunotherapeutics. 15(1). 34–44. 19 indexed citations
13.
Varghese, Lijoy, et al.. (2017). The temporal impact of aging on the burden of herpes zoster. BMC Geriatrics. 17(1). 30–30. 63 indexed citations
14.
Curran, Desmond, Desirée Van Oorschot, Lijoy Varghese, et al.. (2017). Assessment of the potential public health impact of Herpes Zoster vaccination in Germany. Human Vaccines & Immunotherapeutics. 13(10). 2213–2221. 39 indexed citations
15.
Varghese, Lijoy, et al.. (2017). Cost-Effectiveness Assessment Of Herpes Zoster Vaccination In Germany. Value in Health. 20(9). A788–A788. 1 indexed citations
16.
Varghese, Lijoy, et al.. (2016). The Public Health Perspective Of An Investigational Herpes Zoster Vaccine In The United Kingdom (Uk). Value in Health. 19(7). A400–A400. 4 indexed citations
17.
Varghese, Lijoy, Desmond Curran, Eveline M. Bunge, et al.. (2016). Contraindication of live vaccines in immunocompromised patients: an estimate of the number of affected people in the USA and the UK. Public Health. 142. 46–49. 11 indexed citations
18.
Varghese, Lijoy, et al.. (2016). The Public Health Impact Of A New Herpes Zoster Vaccine To The German Population. Value in Health. 19(7). A400–A401. 3 indexed citations
19.
Varghese, Lijoy, et al.. (2015). Estimating the Potential Public Health Impact of Introducing the HZ/su Vaccine in the US Population Aged ≥50 Years. Open Forum Infectious Diseases. 2(suppl_1). 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Justin Carrico Breakdown of academic impact, for papers by Ashleigh McGirr Breakdown of academic impact, for papers by M. Uhart Breakdown of academic impact, for papers by Stephen Kegg Breakdown of academic impact, for papers by Ryan Thompson Breakdown of academic impact, for papers by Doreen Fernsler Breakdown of academic impact, for papers by Fernanda Hammes Varela Breakdown of academic impact, for papers by L Izaley Breakdown of academic impact, for papers by Wirach Maek-a-nantawat Breakdown of academic impact, for papers by Steven J. Sperber
Rankless by CCL
2026